Cargando…
PLA2R Antibody Does Not Outperform Conventional Clinical Markers in Predicting Outcomes in Membranous Nephropathy
INTRODUCTION: The prognostic value of PLA2R antibody (Ab) test in clinical practice remains unclear. We aimed to evaluate its ability in predicting hard outcomes in primary membranous nephropathy (PMN) after adjustments to conventional markers of disease activity. METHODS: A total of 222 patients di...
Autores principales: | Ragy, Omar, Bate, Sebastian, Bukhari, Samar, Hiremath, Mrityunjay, Samani, Syazril, Khwaja, Arif, Rao, Anirudh, Kanigicherla, Durga Anil K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403689/ https://www.ncbi.nlm.nih.gov/pubmed/37547510 http://dx.doi.org/10.1016/j.ekir.2023.05.019 |
Ejemplares similares
-
Can use of the serum anti-PLA(2)R antibody negate the need for a renal biopsy in primary membranous nephropathy?
por: Ragy, Omar, et al.
Publicado: (2023) -
Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen
por: Ragy, Omar, et al.
Publicado: (2023) -
Thromboembolism in nephrotic syndrome: controversies and uncertainties
por: Parker, Kathrine, et al.
Publicado: (2023) -
Longitudinal Analysis of Prophylactic Anticoagulation in Primary Nephrotic Syndrome: Low Incidence of Thromboembolic Complications
por: McDonnell, Thomas, et al.
Publicado: (2023) -
The investigative burden of membranous nephropathy in the UK
por: Hamilton, Patrick, et al.
Publicado: (2019)